Blue Jet Healthcare Ltd

Blue Jet Healthcare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 06 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

For the third consecutive session, Blue Jet Healthcare Ltd has declined, culminating in a fresh 52-week low of Rs 344.6 on 23 Mar 2026. This marks a steep 61.55% drop over the past year, significantly underperforming the Sensex's modest 5.04% decline in the same period.

Blue Jet Healthcare Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change reflects evolving market perceptions amid a challenging price performance and relative sector dynamics, prompting a reassessment of its price attractiveness compared to peers and historical benchmarks.

Blue Jet Healthcare Ltd recorded a robust intraday performance on 18 Mar 2026, surging to a day’s high of Rs 382.55, marking an 8.63% increase. This strong uptick outpaced the Pharmaceuticals & Biotechnology sector and the broader market indices, signalling a notable rebound after a three-day decline.

Blue Jet Healthcare Ltd, a player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs.344.65, marking a significant decline in its stock price amid broader market pressures and company-specific performance factors.

Blue Jet Healthcare Ltd has experienced a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade amid a challenging market backdrop. This recalibration reflects evolving investor sentiment and a reassessment of the company’s price attractiveness relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector.

Blue Jet Healthcare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 06 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Blue Jet Healthcare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 06 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 March 2026, providing investors with the latest insights into its performance and outlook.

Blue Jet Healthcare Ltd witnessed a remarkable surge on 23 Feb 2026, hitting its upper circuit limit with a maximum daily gain of 9.99%, driven by strong buying interest and significant trading volumes. The stock’s performance notably outpaced its sector and the broader market, reflecting heightened investor enthusiasm amid a backdrop of falling delivery volumes and regulatory trading restrictions.

Blue Jet Healthcare Ltd recorded a robust intraday performance on 23 Feb 2026, surging to a day’s high of Rs 390.95, marking a 9.99% increase. This sharp rise outpaced the Pharmaceuticals & Biotechnology sector and the broader market, reflecting heightened trading activity and volatility.

Blue Jet Healthcare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 06 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 February 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Blue Jet Healthcare Ltd’s stock price declined to a fresh 52-week low of Rs.352.75 today, marking a significant milestone in its ongoing downward trajectory. This new low comes amid a series of quarterly results that have reflected subdued sales and profit figures, contributing to the stock’s underperformance relative to the broader market and its sector peers.

Blue Jet Healthcare Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its quality grade downgraded from excellent to good, prompting a sell rating by MarketsMOJO. Despite robust profitability metrics, the company’s recent performance and valuation have raised concerns, reflected in a sharp share price decline and deteriorating returns compared to the broader market.

Blue Jet Healthcare Ltd’s stock declined sharply to a new 52-week low of Rs.357.75 on 16 Feb 2026, marking a significant downturn amid broader market resilience. The pharmaceutical and biotechnology company’s shares have underperformed considerably, reflecting recent quarterly results and sustained downward momentum.

Blue Jet Healthcare Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a sharp decline on 16 Feb 2026, hitting its lower circuit limit amid intense selling pressure. The stock plunged by 9.14% to close at ₹361.0, marking a new 52-week low of ₹357.6 and underperforming its sector by 9.4% on the day.

Blue Jet Healthcare Ltd witnessed a significant intraday decline on 16 Feb 2026, touching a fresh 52-week low of Rs.357.75 as the stock faced intense selling pressure and underperformed its sector and broader market indices.